Crystal of a benzoxazinone compound
Disclosed is a crystal of 2-(hexadecyloxy)-6-methyl-4H-3,1-benzoxazin-4-one useful as a preventive or therapeutic agent for obesity and the like. Specifically disclosed is a crystal of 2-(hexadecyloxy)-6-methyl-4H-3,1-benzoxazin-4-one having a powder X-ray diffraction pattern in which characteristic peaks appear at powder X-ray diffraction interplanar spacings (d) of around 16.54±0.2, 13.26±0.2, 4.70±0.2, 4.38±0.2, and 3.67±0.2λ.
1. A crystal of 2-(Hexadecyloxy)-6-methyl-4H-3,1-benzoxazin-4-one having a powder X-ray diffraction pattern in which characteristic peaks appear at powder X-ray diffraction interplanar spacings (d) of around 16.54±0.2, 13.26±0.2, 4.70±0.2, 4.38±0.2 and 3.67±0.2 angstroms.
2. A solid pharmaceutical composition comprising the crystal of claim 1 and a pharmacologically acceptable carrier.
3. A method for treating obesity comprising administering an effective amount of the pharmaceutical composition of claim 2 to an individual in need thereof.